Volixibat  (Synonyms: SHP626; LUM002)

Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH)^[1][2].

Volixibat (SHP626) (5-30 mg/kg; food intake; daily for 24 weeks) improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

805.95

C₃₈H₅₁N₃O₁₂S₂

1025216-57-2

O=C(N[C@H]1[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(O)=O)O1)O)OCC2=CC=CC=C2)O)NC3=CC=CC([C@H](C4=CC(N(C)C)=CC=C45)[C@@H](O)[C@](CC)(CCCC)CS5(=O)=O)=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Salic K, et al. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolicaspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PLoS One. 2019 Jun 24;14(6):e0218459.  [Content Brief]

  [2]. Palmer M, et al. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol. 2018 Mar 16;19(1):10.  [Content Brief]